Drug intelligence / Profile preview

jiexi

Development stage: Preclinical
Lead developer: Anhui Jiexi Pharm
Administration: Oral

Overview

Jiexi is an intervention being investigated in a randomized controlled clinical trial for the treatment of intestinal dysfunction in moderately severe acute pancreatitis. It is administered orally at a dose of 15ml once daily. The specific composition or detailed mechanism of action of jiexi is not provided in the available context.

Beyond the preview

Go deeper on jiexi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jiexi.

Explore the full profile